Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/115799
Title: Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
Authors: Bisogno, Gianni 
Jenney, Meriel
Bergeron, Christophe
Gallego Melcón, Soledad
Ferrari, Andrea
Oberlin, Odile
Carli, Modesto 
Stevens, Michael
Kelsey, Anna
De Paoli, Angela 
Gaze, Mark N
Martelli, Helene
Devalck, Christine
Merks, Johannes H
Ben-Arush, Myriam
Glosli, Heidi
Chisholm, Julia
Orbach, Daniel
Minard-Colin, Veronique
De Salvo, Gian Luca 
Mesh headings: Antineoplastic Combined Chemotherapy Protocols;Doxorubicin;Rhabdomyosarcoma
Secondary Mesh headings: Adolescent;Child;Child, Preschool;Dactinomycin;Disease-Free Survival;Dose-Response Relationship, Drug;Female;Humans;Ifosfamide;Infant;Male;Vincristine
Issue Date: 2018
Journal: The Lancet. Oncology 
Abstract: 
Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug regimen remains controversial. Therefore, we aimed to evaluate the possible benefit of early dose intensification with doxorubicin in patients with non-metastatic rhabdomyosarcoma.
URI: http://hdl.handle.net/20.500.12857/115799
ISSN: 14702045
DOI: 10.1016/S1470-2045(18)30337-1
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

25
Last Week
0
Last month
checked on May 2, 2021

SCOPUSTM   
Citations

36
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

69
checked on Dec 6, 2021

Page view(s) 5

3
checked on Dec 6, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.